Who is BioStrand?

We are a Belgian BioTech start-up from Hasselt making revolutionary technology for multi-OMICs data analysis.

Our Mission


We, at BioStrand, are on a mission to make omics analysis effective and available for every researcher.

Stream data to create and apply knowledge will revolutionise life sciences.

Today, genomic data analysis is a complex series of operations. Often only specially trained professionals are able to perform these analyses. Costly subscriptions to compute and store these genomic data are needed. Furthermore, omics data reside mostly in silos and integrating these omics data and meta data are difficult. 

To make fundamental progress in life sciences, precision medicine, agriculture and food tech, these problems will have to be tackled first. We, at BioStrand, can solve these problems.


We have created a platform that makes all omics data and meta data actionable and allows analysis by everyone involved in omics research.

Our goal is to provide technology  that can revolutionise genetic research being done in  R&D departments at pharmaceutical, biotechnology, diagnostic, agrochemical and food technology companies.

Contact us today to set up a meeting with one of our experts or request a demo.

Schedule a meeting

Our Innovative Technology

BioStrand offers a revolutionary methodology for identifying similarities and variations in genetic data and detecting structural anchor points that will drive innovation.

BioStrand is the first company since the 1980s to come up with a completely new, out-of-the-box solution for omics data analysis. Where next generation sequencing revolutionised sequence data generation in the last decade, BioStrand now revolutionises sequence data analysis.

The BioStrand methodology enables unprecedented accuracy and speed of operation in detecting similarities and variations in DNA, RNA and proteins. By detecting HYFTSTM, structural 3D information is automatically integrated into the analyses,  revolutionising  pattern and profile detection that are critical in understanding diseases and biological processes.

With our fundamentally new method we make sure that omics data analysis finally can keep pace with data generation.

We unlock the true potential present in omics data and close the gaps towards precision medicine. Just in time.


Our Progress

BioStrand was born from the recognition that omics analysis needed significant improvements.

Founded by a family team with decades of experience in medical research and healthcare, bioIT, big data and NLP, we spent seven years conducting private research about genetic analysis technology and its major barriers, and the potential opportunities. Inspired by cross-domain knowledge stemming from text analytics to evolutionary biology, we developed the formulation of hypotheses, designed algorithms to test them and further expanded our initial ideas. Step by step the project grew until we had a working prototype.

Significant Milestones:

January 1, 2022

We received a €460,000 round of grant funding from VLAIO (Flanders Innovation & Entrepreneurship) for the second time.

August 1, 2021

We released R&R 1.0 as well as the BioStrand data analysis and management platform. Publication of the white paper with the results on the Hasselt University validation study of the R&R algorithm. 

July 1, 2021

We have grown to a team of 15 

November 1, 2020

We released the beta version of R&R 

June 1, 2020

We welcomed our first data scientists/engineers. We received a 235 K Euros Innovation Grant from the Flemish Government

May 15, 2020

We raised 2 M Euros in a seed round. K&E, the Holding behind Globachem invested

April 1, 2020

MVP for first platform finalised

February 6, 2019

We founded the company and filed a patent

Upcoming milestones: Variation analysis to be launched. Extensive NLP possibilities, prediction of 3D protein structure and protein-protein interaction

Our Culture and Values


Outside-the-box thinking is our natural attitude. Innovative ideas arise from creative thinking and fast failure.


Do what you say and say what you do. Achieving great things is only possible when working together in a relationship based on mutual trust and respect.

Shared Success

We operate in a cross-domain environment. Great achievements are always the result of teamwork. The whole is greater than the sum of its parts.

Team-as-a-Family Approach

We are not only colleagues, we are the BioStrand family. Working hard also means having fun and caring for each other.

The Latest


April 14, 2022

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue

VICTORIA, BRITISH COLUMBIA (CANADA), April 14, 2022 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has completed its previously announced acquisition of control over..

Read More

Protein structure prediction: On the route from sequence to function

March 22, 2023

As discussed in our previous blog post in this series, there is a large discrepancy between sequenced proteins and structure-resolved proteins.  This..

Read More

Scaling up structural biology with AlphaFold2

March 15, 2023

The unveiling of AlphaFold2 during the Critical Assessment of Structure Prediction (CASP) 14th edition has been a turning point in the field of..

Read More

Data-Driven Biomedical Research

March 8, 2023

Data-driven biomedical research is the foundation of effective precision medicine (PM). Of course, over the long term, the success of the PM model..

Read More

"Healthy scepticism is the basis of all accurate observation."

- Arthur Conan Doyle